Your browser is no longer supported

For the best possible experience using our website we recommend you upgrade to a newer version or another browser.

Your browser appears to have cookies disabled. For the best experience of this website, please enable cookies in your browser

We'll assume we have your consent to use cookies, for example so you won't need to log in each time you visit our site.
Learn more

Patrick Movsessian

Recent activity

Comments (1)

  • Comment on: New drug class for overactive bladder launched

    Patrick Movsessian's comment 4 July, 2014 6:22 pm

    Beta -3 receptor agonists like Mirabegron should never be used with any patients with atrial fibrillation or any other arrythmias.
    It would be interesting to see whether mirabegron can promote weight loss in OAB patients who are also obese because there is theoretical evidence that beta-3 agonists can act as selective metabolism stimulators.
    Patrick Movsessian